Nasalferon, a new nasal formulation of IFNα2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood

We conducted an experimental protocol with a nasal recombinant IFNα-2b formulation (Nasalferon) in 12 healthy volunteers who received 1 MIU per nostril twice a day, three consecutive days, and studied the induction of biomarkers related to antiviral and immune responses. Nasalferon increases the ant...

Full description

Saved in:
Bibliographic Details
Published inClinical immunology communications Vol. 2; pp. 39 - 45
Main Authors Vázquez-Blomquist, Dania, Bequet-Romero, Mónica, Mendoza-Marí, Yssel, Lemos, Gilda, Valdés, Iris, Canaán-Haden Ayala, Camila, Gonzáles Moya, Isabel, Martínez Rosales, Ricardo, Freyre Corrales, Giselle, Guillén-Nieto, Gerardo
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.12.2022
Elsevier
Subjects
Interferon
Nasal formulation
Nasalferon
Preventive
Preventive
Interferon
Nasal formulation
Nasalferon
Online AccessGet full text

Cover

More Information
Summary:We conducted an experimental protocol with a nasal recombinant IFNα-2b formulation (Nasalferon) in 12 healthy volunteers who received 1 MIU per nostril twice a day, three consecutive days, and studied the induction of biomarkers related to antiviral and immune responses. Nasalferon increases the antiviral biomarker OAS1 transcript levels in oropharynx and PBMCs, regulates molecular and cellular elements related to innate and adaptive immune responses and decreases granulocytes population. These effects support Nasalferon use in virally-exposed populations.
ISSN:2772-6134
2772-6134
DOI:10.1016/j.clicom.2022.02.002